Top

Published in:

01-10-2008 | PRACTICAL PEARL

Lysergic Acid Amide-Induced Posterior Reversible Encephalopathy Syndrome with Status Epilepticus

Authors: Stephane Legriel, Fabrice Bruneel, Odile Spreux-Varoquaux, Aurelie Birenbaum, Marie Laure Chadenat, François Mignon, Nathalie Abbosh, Matthieu Henry-Lagarrigue, Laure Revault D’Allonnes, Pierre Guezennec, Gilles Troche, Jean Pierre Bedos

Published in: Neurocritical Care | Issue 2/2008

Abstract

Introduction

Posterior reversible encephalopathy syndrome (PRES) is known to occur in association with several substances. However, lysergic acid amide (LSA) is not among the previously reported causes of PRES.

Methods

We report on a patient with PRES presenting as convulsive status epilepticus associated with hypertensive encephalopathy after LSA ingestion. Magnetic resonance imaging was performed and catecholamine metabolites assayed.

Results

The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsivant therapy. The clinical history, blood and urinary catecholamine levels, and response to treatment strongly suggest that PRES was induced by LSA.

Conclusion

LSA, a hallucinogenic agent chiefly used for recreational purposes, should be added to the list of causes of PRES.

Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500.PubMedCrossRef

Servillo G, Bifulco F, De Robertis E, et al. Posterior reversible encephalopathy syndrome in intensive care medicine. Intensive Care Med. 2007;33:230–6.PubMedCrossRef

Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665–75.PubMedCrossRef

Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411–7.PubMedCrossRef

Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther. 2004;102:131–8.PubMedCrossRef

Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology. 2007;69:894–7.PubMedCrossRef

Lamy C, Oppenheim C, Meder JF, Mas JL. Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging. 2004;14:89–96.PubMedCrossRef

Cole AJ. Status epilepticus and periictal imaging. Epilepsia. 2004;45(Suppl 4):72–7.PubMedCrossRef

Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65:205–10.PubMedCrossRef

10.

Okeda R, Kawamoto T, Tanaka E, Shimizu H. An autopsy case of drug-induced diffuse cerebral axonopathic leukoencephalopathy: the pathogenesis in relation to reversible posterior leukoencephalopathy syndrome. Neuropathology. 2007;27:364–70.PubMedCrossRef

11.

Lai CC, Chen SJ, Lien SH, Lo CP, Cheng SN. Posterior reversible encephalopathy in a child with Langerhans cell histiocytosis following allogeneic PBSCT treatment with cyclosporine. Eur J Pediatr. 2007; doi:10.1007/s00431-007-0564-2.

12.

Irvin W, MacDonald G, Smith JK, Kim WY. Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol. 2007;25:2484–6.PubMedCrossRef

13.

Nagel S, Kohrmann M, Huttner HB, Storch-Hagenlocher B, Schwab S. Linezolid-induced posterior reversible leukoencephalopathy syndrome. Arch Neurol. 2007;64:746–8.PubMedCrossRef

14.

Minn AY, Fisher PG, Barnes PD, Dahl GV. A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation. Pediatr Blood Cancer. 2007;48:213–7.PubMedCrossRef

15.

Skelton MR, Goldberg RM, O’Neil BH. A case of oxaliplatin-related posterior reversible encephalopathy syndrome. Clin Colorectal Cancer. 2007;6:386–8.PubMedCrossRef

16.

Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43–9006. J Clin Oncol. 2006;24:e48.PubMedCrossRef

17.

Greaves P, Oakervee H, Kon SS, Jones R, Farah N. Posterior reversible encephalopathy syndrome following anti-lymphocyte globulin treatment for severe aplastic anaemia. Br J Haematol. 2006;134:251.PubMedCrossRef

18.

Moawad FJ, Hartzell JD, Biega TJ, Lettieri CJ. Transient blindness due to posterior reversible encephalopathy syndrome following ephedra overdose. South Med J. 2006;99:511–4.PubMedCrossRef

19.

Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354:980–2; discussion-2.PubMedCrossRef

20.

Romano LM, de Robles P, Ioli P, Garcia-Saiz E. [Posterior reversible leukoencephalopathy syndrome caused by cisplatin: a case report.]. Rev Neurol. 2005;41:573–4.PubMed

21.

Shin KC, Choi HJ, Bae YD, Lee JC, Lee EB, Song YW. Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine. J Clin Rheumatol. 2005;11:164–6.PubMedCrossRef

22.

Nakajima M. Posterior reversible encephalopathy complicating intravenous immunoglobulins in a patient with miller-fisher syndrome. Eur Neurol. 2005;54:58–60.PubMedCrossRef

23.

Mavragani CP, Vlachoyiannopoulos PG, Kosmas N, Boletis I, Tzioufas AG, Voulgarelis M. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion. Rheumatology (Oxford). 2004;43:1450–1.CrossRef

24.

Martinez-Garcia FA, Jimenez-Gomez MR, Bixquert-Genoves D, Rodriguez-Hilario H, Meca-Lallana JE, Fernandez-Barreiro A. [Posterior reversible encephalopathy in a 12-year-old female with nephrotic syndrome and methylprednisolone therapy]. Rev Neurol. 2004;39:592–4.PubMed

25.

Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol. 2004;77:72–6.PubMedCrossRef

26.

Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003;122:128–34.PubMedCrossRef

27.

Cosottini M, Lazzarotti G, Ceravolo R, Michelassi MC, Canapicchi R, Murri L. Cyclosporine-related posterior reversible encephalopathy syndrome (PRES) in non-transplant patient: a case report and literature review. Eur J Neurol. 2003;10:461–2.PubMedCrossRef

28.

Lepoivre T, Treilhaud M, Auffray-Calvier E, Rigal JC, Blanloeil Y. [Posterior reversible encephalopathy syndrome: about 2 cases related to the cyclosporine]. Ann Fr Anesth Reanim. 2003;22:466–9.PubMed

29.

Giner V, Fernandez C, Esteban MJ, et al. Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: a case report. Am J Hypertens. 2002;15:465–7.PubMedCrossRef

30.

Russell MT, Nassif AS, Cacayorin ED, Awwad E, Perman W, Dunphy F. Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging. 2001;19:129–32.PubMedCrossRef

31.

Mathy I, Gille M, Van Raemdonck F, Delbecq J, Depre A. Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature. Acta Neurol Belg. 1998;98:347–51.PubMed

32.

Tattersall RS, Boulton JG, Amos RS. Stiff and partly blind–after a first dose of steroid. Lancet. 2008;371:1044.PubMedCrossRef

33.

Ridolfo AL, Resta F, Milazzo L, et al. Reversible posterior leukoencephalopathy syndrome in 2 HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2008;46:e19–22.PubMedCrossRef

34.

Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist. 2007;12:1332–5.PubMedCrossRef

35.

Pinedo DM, Shah-Khan F, Shah PC. Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin. J Clin Oncol. 2007;25:5320–1.PubMedCrossRef

36.

Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007;25:3559.PubMedCrossRef

37.

Vieillot S, Pouessel D, de Champfleur NM, Becht C, Culine S. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol. 2007;18:608–9.PubMedCrossRef

38.

Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63:1475–8.PubMedCrossRef

39.

Saito B, Nakamaki T, Nakashima H, et al. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol. 2007;82:304–6.PubMedCrossRef

40.

Glusker P, Recht L, Lane B. Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab. N Engl J Med. 2006;354:980–1.PubMedCrossRef

41.

Doss-Esper CE, Singhal AB, Smith MS, Henderson GV. Reversible posterior leukoencephalopathy, cerebral vasoconstriction, and strokes after intravenous immune globulin therapy in guillain-barre syndrome. J Neuroimaging. 2005;15:188–92.PubMedCrossRef

42.

Nakazato T, Nagasaki A, Nakamura K, et al. Reversible posterior leukoencephalopathy syndrome associated with tacrolimus therapy. Intern Med. 2003;42:624–5.PubMedCrossRef

43.

Rathi B, Azad RK, Vasudha N, Hissaria P, Sawlani V, Gupta RK. l-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg. 2002;37:203–5.PubMedCrossRef

44.

Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM. Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol. 2001;12:1327–9.PubMedCrossRef

45.

Rodriguez Gomez E, Rodriguez Gomez FJ, Merino MJ, et al. [Reversible posterior leukoencephalopathy, severe hypertension, and cocaine abuse]. Nefrologia. 2001;21:305–8.PubMed

46.

Honkaniemi J, Kahara V, Dastidar P, et al. Reversible posterior leukoencephalopathy after combination chemotherapy. Neuroradiology. 2000;42:895–9.PubMedCrossRef

47.

Lewis MB. Cyclosporin neurotoxicity after chemotherapy. Cyclosporin causes reversible posterior leukoencephalopathy syndrome. BMJ. 1999;319:54–5.PubMed

48.

Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 1998;19:415–7.PubMed

49.

Ito Y, Niwa H, Iida T, et al. Post-transfusion reversible posterior leukoencephalopathy syndrome with cerebral vasoconstriction. Neurology. 1997;49:1174–5.PubMed

50.

Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology. 1997;49:686–9.PubMed

51.

Ozyurek H, Oguz G, Ozen S, et al. Reversible posterior leukoencephalopathy syndrome: report of three cases. J Child Neurol. 2005;20:990–3.PubMedCrossRef

52.

Kamar N, Kany M, Bories P, et al. Reversible posterior leukoencephalopathy syndrome in hepatitis C virus-positive long-term hemodialysis patients. Am J Kidney Dis. 2001;37:E29.PubMedCrossRef

53.

Karp BI, Yang JC, Khorsand M, Wood R, Merigan TC. Multiple cerebral lesions complicating therapy with interleukin-2. Neurology. 1996;47:417–24.PubMed

54.

Leniger T, Kastrup O, Diener HC. Reversible posterior leukencephalopathy syndrome induced by granulocyte stimulating factor filgrastim. J Neurol Neurosurg Psychiatr. 2000;69:280–1.PubMedCrossRef

55.

Al-Ansari M, Todwal A. A 20-year-old man with status epilepticus and uncontrolled hypertension. Chest. 2007;131:309–12.PubMedCrossRef

56.

Marek GJ, Aghajanian GK. Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Drug Alcohol Depend. 1998;51:189–98.PubMedCrossRef

57.

Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71:533–54.PubMedCrossRef

58.

Katzung BG. Basic and clinical pharmacology. 10th edn. Europe: Mc Graw Hill Book company; 2007.

59.

Bunzow JR, Sonders MS, Arttamangkul S, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001;60:1181–8.PubMed

60.

Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001;98:6917–22.PubMedCrossRef

61.

O’Connell PJ, Wang X, Leon-Ponte M, Griffiths C, Pingle SC, Ahern GP. A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood. 2006;107:1010–7.PubMedCrossRef

62.

Alvarez JC, Gluck N, Arnulf I, et al. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther. 1999;66:617–24.PubMed

63.

Spreux-Varoquaux O, Gailledreau J, Vanier B, et al. Initial increase of plasma serotonin: a biological predictor for the antidepressant response to clomipramine? Biol Psychiatry. 1996;40:465–73.PubMedCrossRef

64.

Lewis M, Maddison P. Intravenous immunoglobulin causing reversible posterior leukoencephalopathy syndrome? J Neurol Neurosurg Psychiatr. 2000;69:704.PubMedCrossRef

65.

Moskowitz A, Nolan C, Lis E, Castro-Malaspina H, Perales MA. Posterior reversible encephalopathy syndrome due to sirolimus. Bone Marrow Transplant 2007;39:653–4.PubMedCrossRef

Title: Lysergic Acid Amide-Induced Posterior Reversible Encephalopathy Syndrome with Status Epilepticus
Authors: Stephane Legriel
Fabrice Bruneel
Odile Spreux-Varoquaux
Aurelie Birenbaum
Marie Laure Chadenat
François Mignon
Nathalie Abbosh
Matthieu Henry-Lagarrigue
Laure Revault D’Allonnes
Pierre Guezennec
Gilles Troche
Jean Pierre Bedos
Publication date: 01-10-2008
Publisher: Humana Press Inc
Published in: Neurocritical Care / Issue 2/2008
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI: https://doi.org/10.1007/s12028-008-9096-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lysergic Acid Amide-Induced Posterior Reversible Encephalopathy Syndrome with Status Epilepticus

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2008

False-Positive Presentation of Battle’s Sign During Hepatic Encephalopathy

Stone Silent

Hypothermia for Refractory Status Epilepticus

Safety Issues and Concerns for the Neurological Patient in the Emergency Department

A Comparison of Nicardipine and Labetalol for Acute Hypertension Management Following Stroke

Packed Red Blood Cell Transfusion Causes Greater Hemoglobin Rise at a Lower Starting Hemoglobin in Patients with Subarachnoid Hemorrhage